Phase Ii Trial Evaluating The Combination Of Eribulin (E) Plus Bevacizumab (Bev) As First Line Chemotherapy In Patients With Metastatic Her2-Negative Breast Cancer (Mbc): A Gineco Group Study

A-C. Hardy-Bessard, F. Brocard, M. Leheurteur, A. Melis, J. Dauba,A. Lortholary,B. You, E. Guardiola, J. Grenier, J. Martin-Babau, J. Meunier, P. Follana,A-M. Savoye, A. Mercier-Blas, A. Marti, R. Despax, N. Barbier, N. Gane, P. Ardisson, C. Segura-Djezzar

ANNALS OF ONCOLOGY（2016）

引用 0|浏览12